163622-50-2

Basic information

• Product Name: 4-AMino-5-iodopyrrolo[2,3-d]pyriMidine
• Synonyms: 4-AMino-5-iodopyrrolo[2,3-d]pyriMidine
• CAS NO: 163622-50-2
• Molecular Formula: C₆H₅IN₄
• Molecular Weight: 260.03517
• Mol File: 163622-50-2.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 254.0±50.0 °C(Predicted)
• Appearance: /
• Density: 2.58±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 11.57±0.20(Predicted)
• CAS DataBase Reference: 4-AMino-5-iodopyrrolo[2,3-d]pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMino-5-iodopyrrolo[2,3-d]pyriMidine(163622-50-2)
• EPA Substance Registry System: 4-AMino-5-iodopyrrolo[2,3-d]pyriMidine(163622-50-2)

Safety Data

• Hazardous Substances Data: 163622-50-2(Hazardous Substances Data)

Usage

General Description

4-Amino-5-iodopyrrolo[2,3-d]pyrimidine is a chemical compound categorized under heterocyclic aromatic compounds, specifically pyrrolopyrimidine. It has two rings in its structure: one is pyrrole and the other one is pyrimidine. It's characterized by the presence of an amino group (-NH2) and an iodine atom in its structure. As compounds with this structure are often recognized for their pharmaceutical properties, 4-Amino-5-iodopyrrolo[2,3-d]pyrimidine might hold potential for medical and pharmaceutical research and development. However, detailed information on its specific applications and toxicity is not universally documented, indicating the need for further studies and investigation on this chemical.

Upstream product

• 3680-71-5 Allopurinol 
• 1500-85-2 7-deazaadenine 

Downstream Products

• 1616484-36-6 ethyl 2-(4-amino-5-(1-benzyl-1H-1,2,3-triazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)acetate 
• 1616484-44-6 2-(4-amino-5-(1-benzyl-1H-1,2,3-triazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)acetic acid 
• 1616484-38-8 C₁₈H₁₇N₇O₂ 
• 862729-13-3 4-amino-5-iodo-7-methylpyrrolo[2,3‐d]pyrimidine 
• 1603845-32-4 TX₁-85-1 
• 1603845-25-5 1-(4-(4-(4-amino-3-(4-fluoro-3-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazin-1-yl)ethanone 
• 1603845-26-6 1-(4-(4-(4-amino-3-(3-nitro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)cyclohexyl)piperazin-1-yl)ethanone 
• 1603845-34-6 C₂₁H₂₄FN₇O₄ 
• 1603845-35-7 C₂₇H₂₉N₇O₅ 
• 1603845-36-8 3-(3-nitro-4-phenoxyphenyl)-1-(piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1603845-37-9 tert-butyl (2-(4-(4-amino-3-(3-nitro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)ethyl)carbamate 
• 1603845-38-0 C₂₄H₂₆N₈O₃ 
• 1603845-39-1 (R)-4-(adamantan-1-yl)-N-(2-(4-(4-amino-3-(3-nitro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)ethyl)-2-methylbutanamide 
• 1603845-40-4 C₄₉H₆₄N₈O₈ 

Relevant articles and documents

Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia

A series of pyrrolo[2,3-d]pyrimidine derivatives were prepared and optimized for cytotoxic activities against FLT3-ITD mutant cancer cells. Among them, compound 9u possessed nanomolar FLT3 inhibitory activities and subnanomolar inhibitory activities against MV4-11 and Molm-13 cells. It also showed excellent inhibitory activities in FLT3-ITD-D835V and FLT3-ITD-F691L cells which were resistant to quizartinib. Furthermore, 9u exhibited over 40-fold selectivity toward FLT3 relative to c-Kit kinase, which might reduce myelosuppression toxicity. Cellular assays demonstrated that 9u inhibited phosphorylated FLT3 and downstream signaling factors and also induced cell cycle arrest in the G0/G1 stage and apoptosis in MV4-11 and Molm-13 cells. Oral administration of 9u at 10 mg/kg could achieve rapid tumor extinction in the MV4-11 xenograft model and significantly inhibit the tumor growth in the MOLM-13 xenograft model with a tumor growth inhibitory rate of 96% without obvious toxicity. Additionally, 9u demonstrated high bioavailability (F = 59.5%) and suitable eliminated half-life time (T1/2 = 2.06 h), suggesting that 9u may be a potent candidate for treating acute myelogenous leukemia.

Method for synthesizing 4 -chloropyrropyrimidine compound (by machine translation)

The invention relates to a synthesis method of 4 -lopyrrolopyrimidine compound, which comprises the following steps: mixing 4 -hydroxypyrrolopyrimidine, phosphorus oxychloride and organic base in a temperature range &at;timetimewise and removing excess ethanol to obtain 3 - 7-amino-4 -iodopyrrolopyrimidine; thirdly, dissolving the product 4 -amino-4 -methyl pyrrolopyrimidine in DMF at room temperature and then drying and concentrating 4 -aminopyrrolopyridine. 4 -aminopyrimidine is dissolved in dichloromethane and then subjected to a heat preservation reaction to get -5 -aminopyrrolopyrimidine; and the mixture is dried to remove the solid insoluble matter and is dried and concentrated to yield 12 hours-aminopyrroyrimidine after the heat preservation reaction is carried out; and the solvent is evaporated to remove the solid insoluble matter and is dried and concentrated to remove the solid insoluble matter 4 -5 -7. (by machine translation)

4-amino-pyrimido azacyclo-phenylurea derivatives, and preparation method and application thereof

The invention belongs to the field of chemical medicines, and particularly relates to 4-amino-pyrimido azacyclo-phenylurea derivatives, and a preparation method and application thereof. The structuralformula of the 4-amino-pyrimido azacyclo-phenylurea derivatives is represented by formula I in the specification. In addition, the invention further provides the preparation method and the application of the 4-amino-pyrimido azacyclo-phenylurea derivativess. The 4-amino-pyrimido azacyclo-phenylurea derivative provided by the invention can be used as an FLT3 kinase inhibitor, have a good effect, and provide a new choice for preparing antitumor drugs.